Values of H-Type Hypertension in Patients with Large Vessel Occlusion

Clin Interv Aging. 2024 Nov 21:19:1907-1917. doi: 10.2147/CIA.S488000. eCollection 2024.

Abstract

Background and purpose: Many patients who gained successful recanalization by endovascular treatment (EVT) with acute large vessel occlusion (LVO) did not have the favorable outcome. The study aimed to assess the association between H-type hypertension and clinical prognosis in patients with LVO after receiving EVT.

Methods: Our study enrolled patients from the Endovascular Treatment With versus Without Tirofiban for Stroke Patients with Large Vessel Occlusion (RESCUE BT) Trial. H-type hypertension is defined as patients with hypertension and homocysteine (Hcy) ≥10µmol/L. The primary outcome was a favorable functional outcome, defined as a score of 0-2 on the modified Rankin Scale (mRS) at 90 days. The secondary outcomes were mortality, successful recanalization, futile recanalization, and symptomatic intracerebral hemorrhage (sICH).

Results: The plasma homocysteine level was recorded for 215 patients with hypertension in our study. Among those patients, 172 patients (80%) were founded with Hcy ≥10µmol/L (H-type hypertension), and 43 patients (20%) with Hcy <10µmol/L (non-H-type hypertension). The probability of favorable outcome decreased with homocysteine increasing in patients with hypertension. H-type hypertension was associated with a low probability of favorable outcome (adjusted odds ratio (aOR), 0.38 [95% confidence interval (CI), 0.18-0.80]; p = 0.01) at 90 days. The effects of H-type hypertension on mortality (aOR, 1.90 [95% CI, 0.67-5.39]; p = 0.23) and sICH (aOR, 0.55 [95% CI, 0.13-2.29]; p = 0.41) were not significant.

Conclusion: Our findings suggest that patients with H-type hypertension have a lower likelihood of achieving favorable outcomes but do not have an increased mortality rate within 90 days.

Keywords: H-type hypertension; clinical prognoses; large vessel occlusion.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cerebral Hemorrhage
  • Endovascular Procedures*
  • Female
  • Homocysteine* / blood
  • Humans
  • Hypertension* / complications
  • Male
  • Middle Aged
  • Prognosis
  • Stroke
  • Tirofiban / therapeutic use
  • Treatment Outcome

Substances

  • Homocysteine
  • Tirofiban

Grants and funding

The Second Affiliated Hospital of Army Medical University Talent Development Special Project (2022XKRC002), Outstanding Scientist Family of Chongqing City, National Natural Science Foundation of China (No. 82371334), The Natural Science Foundation of Xiamen (3502Z202374018).